These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 22270052)
1. Enrollment in clinical trials correlates with improved survival in metastatic melanoma. Seetharamu N; Tu TJ; Christos P; Ott PA; Berman RS; Shapiro RL; Osman I; Pavlick AC Oncology; 2011; 81(5-6):403-9. PubMed ID: 22270052 [TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in 1,521 melanoma patients with distant metastases. Barth A; Wanek LA; Morton DL J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677 [TBL] [Abstract][Full Text] [Related]
3. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ; J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000 [TBL] [Abstract][Full Text] [Related]
4. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Bedikian AY; Wei C; Detry M; Kim KB; Papadopoulos NE; Hwu WJ; Homsi J; Davies M; McIntyre S; Hwu P Am J Clin Oncol; 2011 Dec; 34(6):603-10. PubMed ID: 21150567 [TBL] [Abstract][Full Text] [Related]
6. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559 [TBL] [Abstract][Full Text] [Related]
7. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Brand CU; Ellwanger U; Stroebel W; Meier F; Schlagenhauff B; Rassner G; Garbe C Cancer; 1997 Jun; 79(12):2345-53. PubMed ID: 9191522 [TBL] [Abstract][Full Text] [Related]
8. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim K; Hwu WJ; McIntyre S; Hwu P Cancer Invest; 2008 Jul; 26(6):624-33. PubMed ID: 18584354 [TBL] [Abstract][Full Text] [Related]
10. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096 [TBL] [Abstract][Full Text] [Related]
11. A single-institution validation of the AJCC staging system for stage IV melanoma. Neuman HB; Patel A; Ishill N; Hanlon C; Brady MS; Halpern AC; Houghton A; Coit DG Ann Surg Oncol; 2008 Jul; 15(7):2034-41. PubMed ID: 18465172 [TBL] [Abstract][Full Text] [Related]
12. A prognostic model and staging for metastatic uveal melanoma. Eskelin S; Pyrhönen S; Hahka-Kemppinen M; Tuomaala S; Kivelä T Cancer; 2003 Jan; 97(2):465-75. PubMed ID: 12518371 [TBL] [Abstract][Full Text] [Related]
13. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level. Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789 [TBL] [Abstract][Full Text] [Related]
14. Does chemosensitivity-assay-directed therapy have an influence on the prognosis of patients with malignant melanoma stage IV? A retrospective study of 14 patients with malignant melanoma stage IV. Doerler M; Hyun J; Venten I; Potthoff A; Bartke U; Serova K; Hoextermann S; Altmeyer P; Brockmeyer NH Eur J Med Res; 2007 Oct; 12(10):497-502. PubMed ID: 18024256 [TBL] [Abstract][Full Text] [Related]
15. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma. Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515 [TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094 [TBL] [Abstract][Full Text] [Related]
17. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma. Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050 [TBL] [Abstract][Full Text] [Related]
18. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging. Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252 [TBL] [Abstract][Full Text] [Related]
19. Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups? Lim S; Muhs BE; Marcus SG; Newman E; Berman RS; Hiotis SP J Surg Oncol; 2007 Feb; 95(2):118-22. PubMed ID: 17262741 [TBL] [Abstract][Full Text] [Related]
20. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Badgwell B; Xing Y; Gershenwald JE; Lee JE; Mansfield PF; Ross MI; Cormier JN Ann Surg Oncol; 2007 Oct; 14(10):2867-75. PubMed ID: 17671814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]